Hemo Organic Ltd
₹ 10.0
0.00%
25 Apr
- close price
About
Incorporated in 1992, Hemo Organic Ltd manufactures Ayurvedik or Unani pharmaceutical preparation[1]
Key Points
- Market Cap ₹ 3.47 Cr.
- Current Price ₹ 10.0
- High / Low ₹ 15.2 / 8.05
- Stock P/E
- Book Value ₹ -1.13
- Dividend Yield 0.00 %
- ROCE -52.2 %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -27.5% over past five years.
- Promoter holding is low: 16.8%
- Company has high debtors of 2,920 days.
- Working capital days have increased from 9,855 days to 23,725 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.57 | 0.71 | 0.16 | 0.11 | 0.60 | 0.09 | 0.05 | 0.27 | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 | |
| 0.49 | 0.79 | 0.22 | 0.16 | 0.68 | 0.24 | 0.17 | 0.29 | 0.06 | 0.07 | 0.05 | 0.25 | 0.44 | |
| Operating Profit | 0.08 | -0.08 | -0.06 | -0.05 | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.05 | -0.24 | -0.42 |
| OPM % | 14.04% | -11.27% | -37.50% | -45.45% | -13.33% | -166.67% | -240.00% | -7.41% | -500.00% | -600.00% | -2,400.00% | -2,100.00% | |
| -0.72 | 0.23 | 0.02 | -0.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Depreciation | 0.09 | 0.09 | 0.07 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.76 | 0.04 | -0.11 | -0.82 | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.05 | -0.26 | -0.44 |
| Tax % | -1.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -0.76 | 0.04 | -0.11 | -0.82 | -0.08 | -0.15 | -0.12 | -0.02 | -0.05 | -0.06 | -0.05 | -0.26 | -0.44 | |
| EPS in Rs | -2.19 | 0.12 | -0.32 | -2.37 | -0.23 | -0.43 | -0.35 | -0.06 | -0.14 | -0.17 | -0.14 | -0.75 | -1.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -35% |
| 5 Years: | -28% |
| 3 Years: | 0% |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -450% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -3% |
| 3 Years: | -47% |
| 1 Year: | -18% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.40 | 3.40 | 3.40 | 3.40 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 | 3.47 |
| Reserves | -1.96 | -1.92 | -2.16 | -2.98 | -3.06 | -3.21 | -3.33 | -3.35 | -3.40 | -3.46 | -3.52 | -3.78 | -3.86 |
| 0.25 | 0.05 | 0.05 | 0.00 | 0.00 | 0.08 | 0.08 | 0.00 | 0.04 | 0.04 | 0.04 | 1.24 | 1.25 | |
| 0.07 | 0.14 | 0.08 | 0.11 | 0.72 | 0.66 | 0.73 | 0.13 | 0.12 | 0.19 | 0.35 | 0.14 | 0.12 | |
| Total Liabilities | 1.76 | 1.67 | 1.37 | 0.53 | 1.13 | 1.00 | 0.95 | 0.25 | 0.23 | 0.24 | 0.34 | 1.07 | 0.98 |
| 1.23 | 1.12 | 0.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.53 | 0.55 | 0.45 | 0.53 | 1.13 | 1.00 | 0.95 | 0.25 | 0.23 | 0.24 | 0.34 | 1.07 | 0.98 | |
| Total Assets | 1.76 | 1.67 | 1.37 | 0.53 | 1.13 | 1.00 | 0.95 | 0.25 | 0.23 | 0.24 | 0.34 | 1.07 | 0.98 |
Cash Flows
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.36 | 0.06 | 0.06 | -0.78 | -0.15 | -0.12 | -0.04 | 0.01 | -0.01 | 0.00 | 0.11 | -1.19 | |
| 0.41 | 0.02 | 0.00 | 0.70 | 0.02 | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| -0.05 | -0.17 | 0.00 | 0.08 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.20 | |
| Net Cash Flow | 0.00 | -0.09 | 0.07 | 0.00 | 0.01 | -0.06 | -0.01 | 0.01 | -0.01 | 0.00 | 0.11 | 0.01 |
Ratios
Figures in Rs. Crores
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 134.47 | 159.37 | 342.19 | 0.00 | 438.00 | 2,920.00 | 5,402.00 | 94.63 | 2,555.00 | 2,190.00 | 2,920.00 | |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 20.66 | 91.25 | 0.00 | 0.00 | 0.00 | 730.00 | ||
| Days Payable | 392.55 | 3,011.25 | 4,015.00 | |||||||||
| Cash Conversion Cycle | 134.47 | 159.37 | 342.19 | 0.00 | 66.11 | 0.00 | 5,402.00 | 94.63 | 2,555.00 | -1,095.00 | 2,920.00 | |
| Working Capital Days | 70.44 | 97.68 | 228.12 | 232.27 | 146.00 | 689.44 | 438.00 | -67.59 | -1,825.00 | -4,015.00 | 23,725.00 | |
| ROCE % | 0.96% | -10.56% | -7.80% | -12.87% | -19.28% | -40.00% | -42.86% | -11.76% | -43.48% | -75.00% | -250.00% | -52.17% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Apr - Submission of Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the Quarter and Year Ended 31st March, 2025
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E., Monday, 31St March, 2025
31 Mar - Approval of Rights Issue for Rs. 20 Crores.
-
Closure of Trading Window
26 Mar - Closure of trading window from April 1, 2025.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Feb - Newspaper Advertisement for extract of Un-audited Financial Results for the Quarter and Nine Months ended 31st December, 2024.
-
Integrated Filing (Financial)
6 Feb - Integrated financial results for Q3 and nine months ended December 2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Product Profile:[1][2]
Company used to manufacture 2,6 Di Chloro Aniline which is used as an intermediate in bulk drugs and Para Chloro Meta Cresol which is used in the leather industry in its Kheda plant with an installed capacity of 110 MTPA for 2,6 Dichloro aniline and 220 MTPA for para Chloro Meta Cresol. At present, company deals in ayurvedic or unani preparations